Marian Wang: Pfizer is adding yet another twist to its efforts to delay generic competitors. As The New York Times reports, the company seems to have struck a deal with certain pharmacy benefit managers to block generic versions of Lipitor.
Carole Bartolotto: The problem with concluding that GMOs are safe is that the argument for their safety rests solely on animal studies. These studies are offered as evidence that the debate over GMOs is over. Nothing could be further from the truth.
Winona LaDuke: With Keystone XL still delayed, Alberta Clipper is widely seen as the most important and immediate pipeline battle, and thus much of the U.S. tar sands campaign has been shifting its focus to this project.